AIC 284

Drug Profile

AIC 284

Alternative Names: AIC284; BAY-504798; IL2-mutein - AiCuris; Interleukin-2-mutein - AiCuris

Latest Information Update: 10 Mar 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Bayer
  • Developer AiCuris; Bayer
  • Class Antineoplastics; Interleukins
  • Mechanism of Action Immunostimulants; Interleukin-2 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Autoimmune disorders

Highest Development Phases

  • Phase I Autoimmune disorders
  • Discontinued Cancer; HIV infections

Most Recent Events

  • 25 Jan 2016 AIC 284 is available for licensing as of 25 Jan 2016. http://www.aicuris.com/
  • 25 Jan 2016 Phase-I clinical trials in Autoimmune disorders in Germany (Parenteral) (AiCuris pipeline; January 2016)
  • 15 Nov 2004 Phase-I/II clinical trials in HIV infections treatment in USA (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top